Up 45.3%. 2012 Portfolio gain to date based on $219,850 valuation increase less $2,050 interest
Up 38.6%. 2012 Portfolio gain to date based on return on invested capital
Up 21.0%. 2012 Pfizer stock price gain to date including three 22-cent dividends
Up 16.1%. S & P 500 gain to date (1,258 to 1,461)
Note: This portfolio had a steady cost basis of $100,000 from 11/17/04 inception through 6/2/08. From that date through mid-March of 2009, additional funds were invested until the cost basis reached $296,110. The basis has remained steady again since that time.
Note: This portfolio was up by as much as 96K pre-crash on 6/1/07 with the stock closing at $27.68 that day. It was also down as much as 333K on 3/2/09 when the stock closed at $11.66. Gains of 405K from inception were seen on 10/05/12 with the stock at $25.52. Current gains are 405K.
Note: Over time, the leverage factor at these portfolio levels is about 1.9, the lowest since inception. It was designed at the end of 2011 to go up by about 59K per Pfizer point up to $25 on the stock and then 53K a point thereafter. The stock has gotten a little away from me on the upside regarding my covered calls or I would be doing slightly better.
Note: Average annualized gains from inception stands at 11.4% and considers all additional funds needed to margin the naked puts.
Not a bad little increase in portfolio valuation since the end of 2010 if I dare say so. And I do say so. 261K to 482K a year later and then 701K nine months after that. Suddenly my expected million-dollar cashout doesn't seem like such a pipe dream. But then these kinds of gains have to be expected when superior options methods are being utilized.
Correcting typos: The 2011 gain was from 262K to 481K instead of from 261K 462K. If anyone thought that last year's 219K increase in valuation was a fluke, I have now exceeded that with a 220K increase year-to-date in 2012.